Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2021-04-05 Board/Management Inform…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Appointment of Krista Bates as Non-Executive Director 2 pages 77.6KB
Board/Management Information Classification · 95% confidence The document announces the appointment of Krista Bates as a Non-Executive Director of Neurotech International Limited, effective from 5 April 2021. It details her background, experience, and the company's intention to seek shareholder approval for options granted to her. There is no financial data, earnings information, or report publication mentioned. The content is focused on a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short (3190 characters), and it is not an announcement of a report publication or a certification. Therefore, the appropriate classification is MANG with high confidence.
2021-04-05 English
Proposed issue of Securities - NTI 6 pages 30.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Neurotech International Limited. It details the nature of the securities (options), the number to be issued, the proposed issue date, and conditions including shareholder approval at the upcoming AGM. The document is structured as a formal announcement to the ASX (Australian Securities Exchange) and includes references to compliance with ASX Listing Rules and the need for shareholder approval. There is no financial data, financial statements, or detailed report content. The document is not a full report but an announcement of a capital raising or securities issuance event. Therefore, it fits the category of Capital/Financing Update (CAP).
2021-04-05 English
Appendix 2A 15 pages 222.7KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 2A' and is an 'Application for quotation of securities' submitted to the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and the circumstances of the issue, such as options exercised or convertible securities converted. The document is a formal application form used to notify the exchange about new securities to be listed. It is not a financial report, earnings release, or management discussion. It is also not an announcement of a report publication but a regulatory filing related to securities quotation. Therefore, the document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-03-31 English
Human Clinical Trial Update 2 pages 98.8KB
Regulatory Filings Classification · 95% confidence The document is an announcement providing an update on the upcoming commencement of a human clinical trial by Neurotech International Limited. It details the trial design, objectives, and preparations but does not contain any financial data, regulatory filings, or detailed financial reports. The document is relatively short (3679 characters) and serves as an informational update rather than a formal report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification either. The content is best classified as a general regulatory announcement or update about company activities that do not fit other specific categories, making Regulatory Filings (RNS) the most appropriate classification.
2021-03-30 English
Appendix 2A 15 pages 222.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 2A' and is an 'Application for quotation of securities' submitted to the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and the circumstances of the issue, such as options exercised or convertible securities converted. The document is a formal application form related to the listing or quotation of securities on the exchange, which is a regulatory filing required by the exchange for new securities to be officially quoted. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or a certification. The document fits the category of a regulatory announcement related to capital markets but does not fall under capital/financing update (CAP) because it is specifically an application for quotation of securities, which is a regulatory filing. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-25 English
Appendix 2A 15 pages 222.9KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It includes detailed information about the entity, the type of securities being quoted, and the circumstances of the issue, such as options exercised or convertible securities converted. This type of document is a regulatory announcement related to capital markets activity, specifically the quotation of new securities following their issuance or conversion. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement or certification. The document fits the category of Capital/Financing Update (CAP) because it provides an update on the company's capital structure and securities quotation status.
2021-03-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.